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ABSTRACT 
Merkel cell carcinoma (MCC) is an aggressive type of skin cancer. Around 80% of MCCs 
harbor an integrated Merkel cell polyomavirus (MCPyV) genome with a mutation in the large 
T antigen (LT) gene, leading to expression of truncated LT. It is evident that the viral 
truncated LT and small T antigen (sT) play important roles in MCC tumorigenesis. Yet, the 
molecular mechanisms how these viral oncoproteins contribute to MCC development remain 
unclear. The studies presented in this thesis aim to further our understanding of the functional 
role of these MCPyV oncoproteins in MCC tumorigenesis. 
In Paper I, we demonstrated that MCPyV T-antigens induce miR-375, miR-30a-3p and miR-
30a-5p through the DnaJ domain of the viral T-antigen. These miRNAs could target multiple 
autophagy genes (ATG7, SQSTM1 and BECN1) and suppress autophagy in MCC cells. 
Additionally, we showed that both sT and truncated LT also suppress autophagy, but not the 
full-length LT. Inhibition of autophagy, but not pan-caspases, could rescue cell death induced 
by the mTOR inhibitor Torin-1, suggesting that suppression of autophagy is crucial for cell 
survival in MCC. 
In Paper II, we found paranuclear dot-like staining of c-KIT in MCPyV positive (MCPyV+) 
MCC cell lines and tumor samples. Mechanistically, we showed that MCPyV truncated LT 
induces paranuclear retention of c-KIT through its Vam6p binding site. Our results also 
revealed that c-KIT interacts with BECN1. Silencing of c-KIT increased autophagy and 
apoptosis, and decreased LT expression. Inhibition of autophagic degradation in c-KIT 
depleted cells restored the LT expression, suggesting the importance of autophagy 
suppression to sustain the expression of viral oncoprotein and cell survival.  
In Paper III, we showed that overexpression of miR-375 suppressed cell growth and 
migration in MCPyV- MCC cell lines, while suppression of miR-375 decreased cell growth 
and increased apoptosis in MCPyV+ MCC cell lines. The expression of LDHB, a target of 
miR-375, was inversely correlated with miR-375. Silencing of LDHB decreased cell growth 
in MCPyV- MCC cells, but rescued cell growth suppression resulted from miR-375 inhibition 
in MCPyV+ MCC cells. Our findings suggest that miR-375 regulation of LDHB plays 
distinct roles in MCPyV+ and MCPyV- MCC. 
In Paper IV, we demonstrated that MCPyV T-antigens reduce LDHB expression and 
promote glycolysis in MCC. Overexpression of LDHB reduced cell viability and increased 
apoptosis in MCPyV+ MCC cells. Ectopic expression of LDHB reversed the growth-
promoting effect of MCPyV oncoproteins. Inhibition of glycolysis reduced cell growth in 
MCPyV+ MCC cells, while inhibition of mitochondrial respiratory activity inhibited cell 
growth in MCPyV- MCC cells. Our findings suggest that MCPyV+ and MCPyV- MCC cells 
are dependent on different energy metabolism for cell growth. 
Overall, this thesis work highlights the diverse functions of MCPyV oncoproteins and their 
involvement in regulating miRNA expression, autophagy and energy metabolism. 
 x 
LIST OF SCIENTIFIC PAPERS 
This thesis is based on the following papers, which will be referred to in the text by their 
Roman numerals: 
I. Satendra Kumar, Hong Xie, Hao Shi, Jiwei Gao, Carl Christofer Juhlin, 
Viveca Björnhagen, Anders Höög, Linkiat Lee, Catharina Larsson, Weng-
Onn Lui. Merkel cell polyomavirus oncoproteins induce microRNAs that 
suppress multiple autophagy genes.  
Int J Cancer, 2019 Jun 10. doi 10.1002/ijc.32503. 
      
II. Hao Shi, Linkiat Lee, Jiwei Gao, Satendra Kumar, Hong Xie, Vladana 
Vukojevic, Filip Farnebo, Viveca Björnhagen, Anders Höög, Carl 
Christofer Juhlin, Catharina Larsson, Weng-Onn Lui. Merkel cell 
polyomavirus oncoprotein induces paranuclear retention of c-KIT 
suppressing autophagy through interaction with Beclin-1. 
Manuscript 
 
III. Satendra Kumar, Hong Xie , Patrick Scicluna, Linkiat Lee, Viveca 
Björnhagen, Anders Höög, Catharina Larsson, Weng-Onn Lui. MiR-375 
regulation of LDHB plays distinct roles in polyomavirus-positive and -
negative Merkel cell carcinoma.    
Cancers (Basel), 2018 Nov 14, 10: E443. 
 
IV. Satendra Kumar, Patrick Scicluna, Hao Shi, Jiwei Gao, Viveca Björnhagen, 
Anders Höög, Catharina Larsson, Weng-Onn Lui. Merkel cell polyomavirus 
oncoproteins suppress LDHB and promote glycolysis for cell growth.  
Manuscript 
  xi 
CONTENTS 
1 INTRODUCTION ............................................................................................................ 1 
1.1 Merkel cell carcinoma ............................................................................................ 1 
1.1.1 Diagnosis, prognosis and treatment of MCC ........................................... 1 
1.1.2    Mutations, cancer pathways and immune profiles ................................... 4 
1.2 Merkel cell polyomavirus (MCPyV) ..................................................................... 5 
1.2.1 MCPyV T-antigens ................................................................................... 5 
1.2.2 MCPyV integrations, mutations, expressions and functions in MCC 7 
1.3 MicroRNA .............................................................................................................. 8 
1.3.1 Biogenesis and function ............................................................................ 8 
1.3.2 miRNAs in virus-induced tumorigenesis ............................................... 10 
1.4 Autophagy ............................................................................................................ 11 
1.4.1 Molecular mechanism of autophagy regulation ..................................... 12 
1.4.2 Role of autophagy in tumorigenesis ....................................................... 13 
1.5 c-KIT in cancer .................................................................................................... 14 
1.5.1 Activation and function ........................................................................... 15 
1.5.2 Paranuclear c-KIT dot in cancers ........................................................... 16 
1.6 Energy Metabolism .............................................................................................. 16 
1.6.1 Glycolysis and mitochondrial metabolism ............................................. 16 
1.6.2 Metabolic reprogramming in cancer ....................................................... 17 
2 AIMS OF THE STUDY ................................................................................................ 19 
3 MATERIALS AND METHODS .................................................................................. 21 
3.1 Cell lines and MCC primary culture ................................................................... 21 
3.2 MCC tumor samples ............................................................................................ 22 
3.3 RNA extraction and RT-qPCR ............................................................................ 22 
3.3.1 RNA extraction ....................................................................................... 22 
3.3.2 Reverse transcription-quantitative polymerase chain reaction (RT-
qPCR) ...................................................................................................... 22 
3.4 Plasmids................................................................................................................ 22 
3.4.1 MCPyV T-antigens expression plasmids ............................................... 23 
3.4.2 Cellular protein-coding plasmids ............................................................ 23 
3.4.3 Short hairpin RNA (shRNA), miRNA expression and sponges ............ 24 
3.4.4 Reporter constructs .................................................................................. 24 
3.5 Transfection .......................................................................................................... 25 
3.5.1 Lipid-based transfection .......................................................................... 25 
3.5.2 Nucleofection .......................................................................................... 25 
3.6 Protein expression and modification analyses .................................................... 25 
3.6.1 Western blot ............................................................................................ 25 
3.6.2 Immunohistochemistry ........................................................................... 26 
3.7 Protein-protein interaction ................................................................................... 26 
3.7.1 Co-immunoprecipitation ......................................................................... 26 
3.7.2 Immunofluorescence confocal microscopy ............................................ 27 
 xii 
3.8 Autophagy assays ................................................................................................. 27 
3.8.1 Western blot detection of LC3-II ............................................................ 27 
3.8.2 mRFP-GFP-LC3 reporter ....................................................................... 27 
3.8.3 Transmission electron microscopy (TEM) ............................................. 27 
3.9 Cell viability or growth assays ............................................................................ 28 
3.9.1 Trypan blue exclusion assay ................................................................... 28 
3.9.2 WST-1 assay ........................................................................................... 28 
3.10 Apoptosis assays .................................................................................................. 28 
3.10.1 Annexin V assay ..................................................................................... 28 
3.10.2 Cleaved PARP ......................................................................................... 29 
3.11 Metabolic assays .................................................................................................. 29 
3.11.1 Extracellular Acidification Rate (ECAR) ............................................... 29 
3.11.2 Oxygen Consumption Rate (OCR) ......................................................... 29 
3.12 Statistical analyses ............................................................................................... 29 
4 RESULTS AND DISCUSSIONS ................................................................................. 31 
4.1 Involvement of MCPyV T-antigens in miRNAs and autophagy regulation 
(Paper I) ............................................................................................................... 31 
4.1.1 MCPyV T-antigens regulate miRNAs through the DnaJ domain of 
T-antigen ................................................................................................. 31 
4.1.2 MCPyV-regulated miRNAs targets multiple autophagy genes ............. 31 
4.1.3 MCPyV sT and truncated LT regulate autophagy ................................. 32 
4.1.4 Inhibition of autophagy rescues cell death induced by Torin-1 ............ 32 
4.2 Expression and function of c-KIT in MCPyV+ MCC (Paper II) ....................... 32 
4.2.1 MCPyV truncated LT induces paranuclear retention of c-KIT ............. 33 
4.2.2 c-KIT interacts with BECN1 in MCPyV+ MCC cell lines ................... 33 
4.2.3 Silencing of c-KIT induces autophagy and apoptosis in MCPyV+ 
MCC ........................................................................................................ 34 
4.2.4 Autophagy can degrade LT protein ........................................................ 34 
4.3 Functional studies of miR-375 and LDHB in MCC (Paper III) ......................... 34 
4.3.1 miR-375 regulates LDHB levels in MCC .............................................. 35 
4.3.2 miR-375 overexpression suppresses cell growth and migration in 
MCPyV- MCC cell lines......................................................................... 35 
4.3.3 Suppression of miR-375 decreases cell growth and increases 
apoptosis in MCPyV+ MCC cell lines ................................................... 35 
4.3.4 Silencing of LDHB reduces cell growth in MCPyV- MCC cells 
but rescues cell growth suppression mediated by miR-375 
inhibition in MCPyV+ MCC cells .......................................................... 35 
4.4 MCPyV T-antigens and LDHB in glycolysis in MCC (Paper IV) .................... 36 
4.4.1 MCPyV T-antigens regulate LDHB expression and glycolysis ............ 36 
4.4.2 LDHB overexpression reduces cell growth and induces apoptosis 
in MCPyV+ MCC cell lines ................................................................... 36 
  xiii 
4.4.3 Ectopic expression of LDHB reverses the growth-promoting effect 
of MCPyV oncoproteins ......................................................................... 36 
4.4.4 MCPyV + and MCPyV- MCC cells rely on different energy 
metabolism for cell growth ..................................................................... 37 
5 CONCLUSIONS ............................................................................................................ 38 
6 FUTURE PERSPECTIVE ............................................................................................. 39 
7 ACKNOWLEDGEMENTS ........................................................................................... 40 
8 REFERENCES ............................................................................................................... 47 
 
  
 xiv 
LIST OF ABBREVIATIONS 
aa Amino acid 
AGO 
ALTO 
CDS 
CK20 
DNA 
dsDNA 
dsRNA 
ECAR 
Endo H 
ER 
GFP 
GIST 
HBV 
HCV 
HPV 
IF 
IP 
LSD 
LT 
Argonaute protein 
Alternate frame of the large T open reading frame 
Coding sequence 
Cytokeratin 20 
Deoxyribonucleic acid 
Double-stranded deoxyribonucleic acid 
Double-stranded ribonucleic acid 
Extracellular acidification rate 
Endonuclease H 
Endoplasmic reticulum 
Green fluorescence protein 
Gastrointestinal stromal tumor 
Hepatitis B virus 
Hepatitis C virus 
Human papilloma virus 
Immunofluorescence 
Immunoprecipitation 
Large T antigen stabilization domain 
Large T antigen 
MCC 
MCPyV 
miRNA 
MUR1 
MUR2 
NCCR 
 
 
 
Merkel cell carcinoma 
Merkel cell polyomavirus 
microRNA 
MCPyV unique region 1 
MCPyV unique region 2 
Non-coding control region 
 
  xv 
NFP 
NLS 
OCR 
ORF 
ORR 
PCR 
PD-1 
PD-L1 
PNGase F 
pre-miRNA 
pri-miRNA 
RFP 
RISC 
RNA 
RT-qPCR 
SCF 
SCLC 
shRNA 
siRNA 
sT 
UTR 
UV 
 
 
Neurofilament protein 
Nuclear localization signal 
Oxygen consumption rate 
Open reading frame 
Objective response rate 
Polymerase chain reaction 
Programmed cell death protein 1 
Programmed cell death ligand 1  
Peptide:N-glycosidase F 
Precursor microRNA 
Primary microRNA 
Red fluorescence protein 
RNA induced silencing complex 
Ribonucleic acid 
Reverse transcription-quantitative PCR 
Stem cell factor 
Small cell lung carcinoma 
Short hairpin RNA 
Small interfering RNA 
Small T antigen 
Untranslated region 
Ultra-violet 
 
 
    
 
 
 
                   
   1 
1 INTRODUCTION 
1.1 MERKEL CELL CARCINOMA 
Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer, which was first described by 
Toker in 1972 
1
. About 90% of MCCs arise in sunlight-exposed areas, mainly head and neck, 
while some are also found on the trunk and genitals 
2
. MCC mainly occur in the older age 
group (average age, 77 years) and in immunosuppressed patients. The incidence increased 
almost four times in the last two decades in the United States 
3–5
 and almost doubled in 
Sweden from 1993 to 2012 
6
. MCC is a highly metastatic disease; it has approximately 40% 
disease-specific mortality 
4
. Miller at al reported that around half of the patients from a cohort 
of 179 patients with metastatic disease had a median survival of approximately 9 months 
7
.  
           MCC is believed to arise from Merkel cells, a type of mechanoreceptor cell present in 
the stratum basal areas of the epidermis, because they share some common 
immunophenotypes (such as cytokeratin 20, synaptophysin and several endocrine markers) 
and the presence of neurosecretory granules 
8,9
. However, several pieces of evidence argue 
against this. For example, neural cell adhesion molecule L1 (CD171) and tyrosine kinase 
receptor c-KIT are detected in most MCCs but not in Merkel cells 
10
. Furthermore, Merkel 
cells are differentiated and post-mitotic, while MCCs are highly proliferative 
11
. Interestingly, 
MCCs commonly express pre-/pro-B specific expression markers (TdT and PAX5) and 
immunoglobulins, suggesting that early B cells may represent putative progenitors of MCC 
12
.  
          About 80% of MCCs are infected with Merkel cell polyomavirus (MCPyV), which was 
discovered by Moore and Chang in 2008 
13
. Despite that MCPyV is widespread in the general 
population, integration of mutated viral DNA into the host genome and expression of viral T-
antigens are only detected in MCCs 
14
. Importantly, the viral T-antigens are required for 
neoplastic transformation and maintenance of MCC cell growth 
15
, supporting their important 
roles in the pathogenesis of MCC. An introduction of MCPyV T-antigens and their 
involvement in MCC tumorigenesis is described in Chapter 1.2. Besides MCPyV, ultra-violet 
(UV) exposure is another etiology of MCC. MCPyV and UV-associated MCCs are 
molecularly distinct (for details, please refer to Chapter 1.1.2). 
1.1.1  Diagnosis, prognosis and treatment of MCC 
Three types of MCC are recognized based on histological features: intermediate, small cell 
and trabecular 
16
. The trabecular type is a well-differentiated form with a better prognosis, 
while the small cell type is undifferentiated with worse prognosis. The intermediate type has 
more mitotic activity 
4,17
.  
           MCC is generally characterized by expressions of cytokeratin 20 (CK20) with a 
paranuclear dot-like staining pattern and neuroendocrine markers such as neuron-specific 
enolase (NSE), synaptophysin and chromogranin A 
18
. Most MCCs are MCPyV positive 
(MCPyV+), therefore immunostaining of MCPyV LT can be used to identify virus-associated 
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MCCs. However, the virus-negative MCCs are hard to be diagnosed and differential 
diagnosis is necessary to distinguish MCC from other common neuroendocrine tumors, such 
as small cell lung carcinoma (SCLC), melanoma and cutaneous lymphoma (Table 1).  
 
Table 1. Immunohistochemical staining used for differential diagnosis of MCC  
 CK20 CK7 NSE TTF1 S100 LCA 
Merkel cell carcinoma + - + - - - 
Melanoma - - - - + - 
Small cell lung carcinoma - + + + - - 
Cutaneous lymphoma - - - - - + 
CK20, cytokeratin 20; CK7, cytokeratin 7; NSE, neuron-specific enolase; TTF-1, thyroid 
transcription factor 1; LCA, leucocyte common antigen. + and – refer to presence or absence 
of the staining, respectively. Adapted from Jaeger et al (2012) 19. 
            
 Based on the American joint committee on cancer (AJCC) and the European 
consensus-based interdisciplinary guidelines, clinical/ histological features, distant tissue 
involvement and staging system should be employed for prognostic classification of MCC 
17,20,21
. Larger primary tumor size is associated with an increased risk of metastasis and 
sentinel lymph node biopsies are required for all the patients with primary tumor 
22
. 
According to Surveillance, epidemiology and end results (SEER) data from 3870 MCC cases, 
10-years survival rate was less in male (50%) than female (65%) patients 
4
. Patients with 
local disease had 64% of five years survival rate, as compared to 40% in regional nodal 
disease and 18% in metastatic disease 
23,24
. However, there were no significant differences 
observed in survival rate between different age groups 
4
. Till date, no robust prognostic 
marker has been reported for MCC patients, however some reports showed that lack of 
lymphatic vessels invasion and T-cell infiltration can be used as a good prognosis indicator 
for MCC patients 
20,25,26
.  
          AJCC classified MCC staging based on three important indicators: tumor size and 
invasiveness of the primary tumor (T), degree of lymph node involvement (N) and metastatic 
state (M). Yiengpruksawan et al provided the first staging system for MCC, which defined 
tumor restricted to the skin as stage I, nodal metastasis as stage II, and distant metastasis as 
stage III and stage IV 
27
. The overall staging for MCC is shown in Table 2. 
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Table 2. MCC staging and prognosis based on national cancer database 
Stage T N M 5-year survival 
0 TIS N0 M0  
IA T1 pN0 M0 79% 
IB T1 cN0 M0 60% 
IIA T2/T3 pN0 M0 58% 
IIB T2/T3 cN0 M0 49% 
IIC T4 N0 M0 47% 
IIIA Any T N1a M0 42% 
IIIB  N1b/N2 M0 26% 
IV  Any N M1 18% 
T = primary tumor, N = degree of lymph node involvement, M = metastatic state, TIS = in 
situ primary tumor, pN0 = nodes negativity by pathologic examination, cN = nodes clinically 
detectable. Adopted from Lemos et al (2012) 17. 
          
 The choice of treatments for MCC depends on the stage of the tumor and health of the 
patient. Generally, wide surgical excision with 1-2 cm margins, followed by radiotherapy is 
used for treatment of the primary tumor. Chemotherapy regimens such as platinum-based, 
taxanes, anthracyclines and etoposide are considered as systemic therapeutic agents for 
treatments of advanced MCC. However, these drugs have less durable responses and no 
significant effects on survival rate. Chemotherapy is now considered to play a palliative role 
28
. In the past few years, several new targeted therapies have been investigated as treatment 
options for treatment of advanced and metastatic MCC. For examples, YM155, a small 
molecule inhibitor targeting survivin, induces cell death in MCPyV+ MCC cell lines and 
xenograft 
29,30
. ABT-263 is a potent inhibitor for the anti-apoptotic Bcl-2 family members, 
which induces apoptosis in MCC cell lines and xenograft 
31,32
; however, this drug did not 
show any significant effect in a phase II trial 
33
. Although KIT mutations are rarely found in 
MCC, its overexpression has been observed in MCC tumors 
34,35
. Several MCC patients have 
been successfully treated with imatinib, a small molecule tyrosine kinase inhibitor that blocks 
c-KIT activation 
36–38
. However the results from a phase II trial of imatinib in MCC were 
disappointing since a majority of patients progressed within 1 to 2 cycles of treatment, 
indicating its limited clinical benefit for MCC patients 
39
. Furthermore, Pazopanib, which can 
inhibit several receptor tyrosine kinases including, FGFR, PDGFR, VEGFR and c-KIT, has 
demonstrated some clinical beneficial effects in a single MCC patient 
40
.  
         Both MCPyV+ and MCPyV- MCC tumor cells express programmed cell death ligand 1 
(PD-L1), with PD-L1 expression being more frequently detected in MCPyV+ tumor cells 
than MCPyV- MCC tumor cells 
41
. The PD-L1 expression pattern in MCC tumor cells 
supports the ideas to use PD-1 signaling pathways for targeted therapy in advanced MCC 
patients. Several phase II trials are ongoing to use anti-PD-1 and/or anti-PD-L1 checkpoint 
inhibitors for MCCs patients. These inhibitors showed durable response in advanced MCC 
patients pre-treated with chemotherapy 
41–43
. For example, avelumab (anti-PD-L1 antibody) 
was used to treat 88 MCC patients with metastatic disease and found that 32.8 % had 
objective response rate (ORR), including complete and durable response in 9.1 % patients, 
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which were also associated with improved quality of life 
43
. In another study with 
pembrolizumab (anti-PD-1 antibody) as a first line therapy, 56 % achieved ORR, including 
complete response in 15.4 % of the patients 
41
. Presently, these two checkpoint inhibitors 
(avelumab and pembrolizumab) are approved by the Food and Drug Administration (FDA) to 
treat MCC.  
1.1.2   Mutations, cancer pathways and immune profiles 
MCPyV is an established etiology for MCC, and the remaining 20% of MCPyV- MCCs are 
regarded as having a UV radiation etiology. These two groups are also known to display 
different genomic mutation profiles. While MCPyV+ tumors exhibit less somatic mutations 
and copy number alterations, MCPyV- tumors have higher mutational burden. MCPyV+ 
tumors have around 25-fold less mutation frequency compared to UV-associated tumors
44–46
. 
Notably two key tumor suppressor genes, RB1 and TP53, are frequently mutated in UV-
associated MCCs, but not in MCPyV+ MCCs; however, their functions are inactivated by 
MCPyV T-antigens in MCPyV+ tumors 
45,47–50
. In addition, MCPyV- MCCs carry 
inactivating mutations in genes involved in several cancer pathways, such as 
PI3K/Akt/mTOR, Notch, Wnt signaling, DNA damage repair and chromatin modifying 
pathways 
44,46,48,51
.  
          Based on global mRNA profiles, gene expression patterns in MCC are distinct from 
other primary cutaneous carcinomas 
52
. As compared to squamous cell carcinoma, MCCs had 
higher levels of CK20, chromogranin A, synaptophysin, AKT3, FYN, RAB3B, JUND, FEV, 
SOX2, BCL2, MYCL1, VEGFA, GPC3, ATOH1, HIP1 and c-KIT. On the other hand, genes 
involved in Hedgehog signaling, including GL1, GLI2, PTCH1 and PTCH2, were higher 
expressed in basal cell carcinoma compared to MCC. Notably, the gene expression signatures 
of MCPyV+ and MCPyV- MCCs were also distinct 
52
. Among the differentially expressed 
genes, MCPyV- tumors had higher expressions of transcripts involved in Notch signaling 
(such as DLL1, CTBP2, HES1, JAG2 and JAG1) and receptor tyrosine kinase signaling (e.g. 
FGFR2, VEGFA, PDGFA, FGF14, FGF11 and FGF9). In addition, increased expression of 
immune response genes were also observed in MCPyV+ as compared to MCPyV- MCCs 
52
. 
Importantly, the immune response gene signature, especially genes associated with cytotoxic 
CD8 lymphocytes, is associated with a good prognosis in MCC 
53
. In line with the 
transcriptome analysis, tumor-infiltrating immune cells are associated with favorable survival 
in MCC 
26,53–55
. Although several immune response genes are higher expressed in MCPyV+ 
than MCPyV- MCCs, both MCPyV+ and UV-associated MCCs are immunogenic 
56
. It is 
now clear that MCC can evade the immune response using the PD-1/PD-L1 immune-
checkpoint pathway. Most MCC tumors express PD-L1, which binds to its receptor PD-1 on 
T cells 
48,57
, leading to inhibition of T cell killing of tumor cells. Therefore, targeting the PD-
1/PD-L1 immuno-checkpoint has become a promising therapy for MCC patients.  
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1.2 MERKEL CELL POLYOMAVIRUS (MCPyV) 
MCPyV is a circular double-stranded DNA (dsDNA) virus, which belongs to the 
Polyomaviridae family. The genome is about 5.4 kb and harbors early and late regions 
separated by a non-coding control region (NCCR). The early region contains the T-antigen 
gene locus, the late region encodes the capsid proteins and the NCCR contains the bipartite 
origin of replication. Besides viral proteins, MCPyV also contains gene for a single 
microRNA (mcv-miR-M1) which is located in an antisense direction to the early region that 
negatively regulates early transcripts and limits viral DNA replication 
58
. 
1.2.1  MCPyV T-antigens 
The T-antigen locus generates multiple alternatively spliced transcripts, namely large T (LT), 
small T (sT), 57 kT and alternate frame of the large T open reading frame (ALTO). Domain 
structures of various T-antigens are shown in Figure 1, and their functions are summarized in 
the following sections. 
1.2.1.1 Large T-antigen 
The LT of MCPyV includes several conserved features (such as DnaJ, Rb binding motif, 
origin binding domain (OBD), zinc finger and ATPase/helicase) and two unique regions 
called MCPyV unique regions 1 and 2 (MUR1 and MUR2). The DnaJ domain comprises of 
the CR1 (LXXLL) and the Hsc70 binding (HPDKGG) motifs, which is required for viral 
replication 
58
 and growth promoting activity 
59
. The Rb binding motif (LXCXE) is flanked by 
MUR1 and MUR2. This motif is highly conserved across polyomaviruses and is required for 
cell cycle progression through up-regulation of E2F target genes and survivin 
60,61
. MUR1 has 
a Vam6p binding site, in which the interaction disrupts lysosomal trafficking by sequestration 
of Vam6p to the cell nucleus 
62
. The functional role of nuclear sequestration of Vamp6 
remains unclear, however it is known that Vam6p can regulate MCPyV replication in vitro 
63
, 
and it is not essential for promoting cell growth 
60
. MUR2 has a nuclear localization signal 
(NLS, RKRK motif) 
64
. The NLS was initially found to be conserved in MCC tumors and 
regarded as functionally important in MCC pathogenesis, but recent findings showed that this 
motif is not always preserved in the MCC-specific truncated LT and is not required for the 
growth promoting activity of LT 
60
. Several key domains in the carboxyl-terminal of LT are 
required for viral replication. The OBD recognizes and binds the viral origin of replication in 
the NCCR, the zinc finger motif and the ATPase/helicase domains are required for replication 
initiation. Although the helicase domain of SV40 directly binds to p53, this domain in 
MCPyV cannot interact with p53 
64,65
.  
 
1.2.1.2 Small T antigen 
MCPyV LT and sT share exon 1 of the T antigen, therefore they have the common DnaJ 
domain in the amino-terminal. The carboxyl-terminal of sT carries unique features, including 
LT-Stabilization Domain (LSD), and protein phosphatase 2A and 4C (PP2A and PP4C) 
binding sites. As aforementioned, the DnaJ domain of LT is required for viral replication, 
however mutation of this domain in sT does not affect MCPyV replication 
59
. The function of 
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this domain remains elusive. A major feature of MCPyV sT is the LSD, which has been 
shown to inhibit Fbw7 ubiquitin ligase, thereby stabilizing LT, c-Myc and cyclin E. 
Stabilization of these proteins is important for viral replication and transformation 
66
. The 
LSD also targets 4E-BP1 and prevents the turnover of its hyperphosphorylated form, which 
increases eIF4F activity and in turn, mitotic-dependent protein translation 
15,66
. 
          The PP2A domain is known to be the primary function of sT in other polyomaviruses 
such as SV40, in which sT binds PP2A by competing with B subunit (one of the subunits in 
the PP2A heterotrimeric complex) and inhibits Akt-mTOR signaling, leading to cell cycle 
progression, survival and differentiation 
67–69
. However, PP2A binding of MCPyV sT is not 
required for transformation activity 
32,70
; this is likely due to limited B subunit targeting in the 
MCPyV sT compared to the sT in SV40 and other polyomaviruses. PP4C and/or PP2A Aβ of 
MCPyV sT interact with NF-kB essential modulator (NEMO) protein and disrupt host cell 
inflammatory signaling mediated by NF-kB 
71
. The PP4C site is also important for promoting 
cell motility and migration by destabilization of microtubules through inhibition of stathmin 
phosphorylation, a key microtubule binding protein 
72,73
. MCPyV sT induces cell motility 
through Rho-GTPase, which induces filopodium formation in MCC 
74
. This effect may 
explain the highly metastatic nature of MCC tumors. Additionally, sT induces aerobic 
glycolysis through induction of monocarboxylate transporter (MCT1) that regulates MCC 
cell proliferation and viability 
75
. sT can also induce motility and invasiveness by inducing Cl
-
-channel proteins CLIC1 and CLIC4 
74
 or cellular sheddase proteins ADAM 10 and ADAM 
17 
76
.  
 
1.2.1.3 57 kT and ALTO 
The 57 kT is an alternatively spliced T-antigen of 432 amino acids. It shares the first 332 and 
the last 100 amino acids with LT, including the DnaJ domain, Rb binding site, MURs and 
nuclear localization signal, but lacks the OBD and most of the helicase domain. Although the 
functional role of the 57 kT is still unclear, Cheng et al showed that the full-length 57 kT and 
the carboxyl-terminal of 100 residues encoded from exon 3 of the 57 kT has a growth 
inhibition function 
77
. ALTO is encoded by an alternative ORF of LT, which is evolutionally 
related to the middle T antigen of murine polyomavirus. ALTO is expressed during viral 
replication, however it is not essential for MCPyV genome replication in vitro 
78
 and cell 
growth in MCC cells 
60
.  
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1.2.2  MCPyV integrations, mutations, expressions and functions in MCC 
As aforementioned, MCPyV infection is widespread in the general population. However, the 
tumorigenic MCPyV can be distinguished from the non-tumorigenic ones based on the 
presence of viral DNA integration and LT mutations. MCPyV has been shown to 
monoclonally integrate into the genome of MCC tumors 
14,79,80
. The viral integration sites 
have been identified within or in the vicinity of several cellular genes, including PTPRG, 
GMDS, DENND1A, SNAT1, IL20RA, SRD5A2L2 and MYC; however no recurrent viral 
integration site has been identified. 
         All MCPyV+ MCC tumors harbor LT mutations (point mutations or small indels) that 
lead to expression of truncated LT (Figure 1). These mutants retain Rb binding but eliminate 
Figure 1. Functional domains of various MCPyV T-antigens. The T-antigen locus of 
MCPyV encodes four spliced transcripts. LT is 816 amino acids in size, containing 
DnaJ domain, retinoblastoma (Rb) binding motif, MCPyV unique regions 1 and 2 
(MUR1 and MUR2), origin binding domain (OBD), zinc finger motif and 
ATPase/helicase. LT mutations are commonly found in MCC tumors, in which the 
mutation sites are located downstream of the Rb binding site. sT, 186 amino acids in 
length, shares the same DnaJ and Hsc70 binding domain of LT, and carries unique 
features LT-Stabilization Domain (LSD), protein phosphatase 2A and 4C (PP2A and 
PP4C) binding sites at its carboxyl-terminal. 57 kT, 432 amino acids in length, also 
shares the DnaJ domain with LT and sT, and contains the MUR1 region, Rb binding 
domain and exon 3 of LT. ALTO encodes 200 residues of MUR region of LT and 
OBD, which is closely related to middle T antigen of murine polyomavirus. 
  8 
viral replication capacity. Besides the truncated LT, most MCPyV+ MCC tumors also 
express intact sT 
15
, and some has truncated ALTO 
78
. Despite the functional role of truncated 
ALTO remains to be characterized, both truncated LT and sT are required for cellular 
transformation and tumorigenesis in vitro and in vivo 
15,32,77,81–83
. Furthermore, these T-
antigens are also necessary for the maintenance of cell growth in MCPyV+ MCC cells 
84
.  
 
1.3 MICRORNA 
microRNA (miRNA) was first discovered in Caenorhabditis elegans (C. elegans) by the 
Ambros and Ruvkun groups 
85,86
. They found that lin-4 binds to its complementary sequence 
in the 3´ untranslated region (UTR) of lin-14 and down-regulate its translation. However, the  
miRNA field only started to emerge after the discovery of the highly conserved miRNA 
called lethal-7 (let-7) in 2000 
87
. Let-7 was detected in a wide range of animal species, 
including human 
88
. This finding inspired several groups to search for miRNAs in different 
organisms. In 2001, about 100 miRNAs had been discovered in fly, worm and human 
89–91
. 
1.3.1  Biogenesis and function 
The biogenesis of miRNAs starts from the transcription of the miRNA-encoding gene by 
RNA polymerase II, this primary transcript is called primary miRNA (pri-miRNA) 
92,93
. This 
pri-miRNA is self-complementary and forms a hairpin structure with some imperfect base 
pairing 
94
, which is captured by an enzyme complex of Drosha (RNase type-III) and 
DiGeorge syndrome critical region gene 8 (DGCR8) that processes the pri-miRNA into the  
precursor miRNA (pre-miRNA) with a 2-nucleotide overhang at the 3´end; this complex is 
also termed as microprocessor complex 
92,95–97
. After that, the pre-miRNA is transported from 
nucleus to the cytoplasm via exportin-5 (XPO5) in association with RAN-GTP. In the 
cytoplasm, the pre-miRNA is further processed by another dsRNase type-III enzyme called 
Dicer 
95,98
. Dicer has N-terminal helicase activity, which helps in the processing of a double-
stranded miRNA duplex. This miRNA duplex is actively incorporated into RNA induced 
silencing complex (RISC), resulting in the formation of RISC loading complex (RLC) 
99
. 
Subsequently one strand of the miRNA duplex, called guide strand, is incorporated into the 
complex, while the other strand (passenger strand) is removed from the complex 
100
. The   
miRNA biogenesis is schematically illustrated in Figure 2. 
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             miRNAs  mostly functions by complementary base pairing with 3’UTR, but 
occasionally in the 5´UTR or coding sequence of the target mRNAs 
101–104
. These interactions 
can either lead to degradation of target mRNA or inhibition of translation, depending upon 
the degree of base pairing. If there is more base-pairing or complete base pairing to the target 
mRNA, it is more likely to be degraded; in case of less number of base pairing or incomplete 
base pairing, it will lead to translational inhibition 
105–107
.  
Figure 2. An overview of miRNA biogenesis and its mode of action. miRNA is 
transcribed from the host miRNA gene by RNA polymerase II and formed pri-miRNA, 
which is further processed by Drosha and DGCR8 protein complex to form pre-miRNA 
and then transported to the cytoplasm from nucleus by exportin 5. DICER and TARBP2 
protein complex further processes the pre-miRNA into mature miRNA, which is then 
loaded into the RISC complex. miRNA binds to specific mRNA and degrades its target 
via translation repression or mRNA degradation depending on the degree of sequence 
complementarity between miRNA and mRNA. 
  10 
1.3.2  miRNAs in virus-induced tumorigenesis 
Several human viruses are known to cause cancers, such as Epstein-Barr virus (EBV), 
Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T-lymphotropic virus I (HTLV-
I), human papillomavirus (HPV), Kaposi’s sarcoma herpesvirus (KSHV) and MCPyV 108–
115
. Among these, some are known to express viral oncogenes that directly contribute to 
cancer development through regulation of tumor suppressor pathways (such as Rb and 
p53), as well as other common targets that play important roles in tumorigenesis, including 
NF-ĸB, AKT-mTOR, autophagy and immune evasion. In this section, several examples of 
how miRNAs are involved in viral oncogenesis are described. 
1.3.2.1 Hepatitis B/C (HBV or HCV)-associated hepatocellular carcinoma 
Chronic infection with HBV and/or HCV is one of the known factors that contribute to 
hepatocellular carcinoma development. Although the mechanisms by which the viruses 
induce cellular transformation and tumorigenesis remain unclear, several pieces of evidence 
indicate the involvement of miRNAs in the pathogenesis of this tumor type. Several cellular 
miRNAs are known to regulate HBV and HCV gene expression and replication. For 
example, miR-199a-3p, miR-210, miR-92a, miR-20a and miR-224 directly regulate HBV 
genes that reduce viral replication 
116–118
, while some miRNAs (miR-1, miR-372/373, miR-
141 and miR-122) can modulate HBV replication by targeting the cellular genes that 
regulate viral replication, such as farnesoid X receptor α, nuclear factor I/B, peroxisome 
proliferator-activated receptor alpha and cyclin G1 
119–121
. For HCV, miR-122 binds directly 
to HCV RNA, which enhances HCV translation and replication 
122
. Inhibition of miR-122 
effectively blocks HCV replication in human and chimpanzee 
123
; 
124
. Additionally, miR-
141, miR-199a, miR-29, let-7b, miR-130a, miR-27a, miR-196 and miR-448 can also 
regulate HCV replication through direct interaction of HCV RNA or indirectly via cellular 
targets 
125–131
. 
         Besides viral replication, viral proteins have also been shown to regulate miRNA 
expression that promotes tumorigenesis. For example, hepatitis B virus protein X (HBx, 
one of the transactivators that plays a crucial role in the hepatocellular carcinogenesis) 
represses miR-148a-mediated suppression of HPIP (a key regulator of tumorigenesis) that 
enhances tumorigenesis in a mouse model of hepatocellular carcinoma 
132
. HBx also 
modulates multiple miRNAs, including miR-216b, miR-373, miR-15b and miR-205, while 
HBV preS2 (another transactivator of HBV) represses miR-338-3p that lead to the 
development or progression of hepatocellular carcinoma 
133–138
. 
 
1.3.2.2 Human papillomavirus (HPV)-associated cervical cancer 
Persistent infection with high-risk human papillomavirus (HPV), such as HPV 16 and 18, is 
a cause of cervical cancer 
139
. This virus encodes two key oncoproteins, i.e. E6 and E7, 
which promote tumorigenesis by inhibiting the p53 and RB tumor suppressor, respectively. 
These two viral oncoproteins are also known to regulate miRNAs that play crucial roles in 
oncogenic pathways 
139
.  
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          The high-risk HPV E6 has been shown to suppress several miRNAs resulting from 
the E6-mediated destabilization of p53, such as miR-34a, miR-23b and miR-145 
139–141
. 
These miRNAs are transcriptionally activated by p53 and play an important role in p53 
tumor suppression. The HPV E7 interacts with Rb and inhibits its binding to E2F, thereby 
promoting cell cycle progression through E2F-mediated transcription 
142
. Similar to the E6-
mediated effect of p53-regulated miRNAs, HPV16 E7 has been shown to regulate miR-15b 
143
, which is a transcriptional target of E2F1 
144
. Additionally, HPV16 E7 also induces miR-
27b that regulates cell proliferation and apoptosis in cervical cancer cells through polo-like 
kinase 2 
145
, and suppresses miR-203-mediated repression of p63 upon epithelial 
differentiation 
146
. A few miRNAs have been implicated to regulate HPV DNA replication 
or gene expression. miR-203, miR-145 and miR-125b can inhibit HPV genome 
amplification 
146–148
, while miR-375, miR-875 and miR-3144 directly suppress HPV 
transcripts 
149
. 
1.3.2.3 MCPyV-associated MCC 
As aforementioned, MCPyV plays an important role in MCC tumorigenesis. Our group 
previously identified specific miRNAs associated with MCPyV status, tumor metastasis 
and disease-specific survival in MCC patients 
150
, suggesting the importance of miRNAs in 
MCC development and progression. Importantly, miR-375 is highly abundant and specific 
for MCC and its serum levels correlate with tumor burden in MCC 
151
. However the 
functional role of miRNAs in MCC pathogenesis is still poorly understood. To date, only 
two miRNAs, miR-203 and miR-375, have been functionally characterized in MCC. miR-
203 can inhibit cell growth and induce cell cycle arrest in MCPyV- MCC cells 
150
, while 
miR-375 can regulate neuroendocrine differentiation, cell growth, autophagy and glycolysis 
in MCC cells 
152–154
. In addition, Theiss et al demonstrated that mcv-miR-M1 (a miRNA 
encoded by the MCPyV) suppresses early viral transcripts and limits DNA replication of 
viral episomes 
155
.  
 
1.4 AUTOPHAGY 
About 50 years ago, the term “autophagy” was given for the first time by Duve et al 156. It is a 
Greek word, meaning self-eating property. Autophagy is a cellular degradation process 
required for development, differentiation, survival and maintaining the homeostasis of the 
cells 
157
. Autophagy is mainly divided into three types, namely macro-autophagy, micro-
autophagy and chaperone-mediated autophagy (CMA) 
158
, which differ on the basis of 
transportation of cytoplasmic material to the lysosomes. Macro-autophagy is the most 
common type of autophagy, which involves double membrane vesicles called 
autophagosomes containing cellular proteins and damaged organelles which are subsequently 
delivered to lysosomes for degradation 
159
. Micro-autophagy involves projections of the 
lysosomal membrane that capture the cargo molecules, and CMA involves chaperone 
proteins that recognize the cargo proteins, then unfold and translocate them directly across the 
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lysosomal membrane 
160,161
. As my thesis work mainly focused on macro-autophagy, a brief 
description of this process is given below. 
 
1.4.1 Molecular mechanisms of autophagy regulation 
Autophagosome formation requires autophagy related genes called ATGs 
162
. The autophagy 
process is divided into three main steps: initiation, nucleation and expansion (Figure 3). 
          Initiation requires the unc-51-like kinase 1 (ULK1) complex, which contains ULK1 
and ATG13. Induction of autophagy, due to any stress condition or activation signal by 
signaling molecules, releases the ULK1 complex from mTORC1. ULK1 translocates to the 
autophagy initiation sites and activates recruitment of a second kinase complex containing 
VPS34, BECN1, VPS15 and ATG14 
163
, which leads to production of PI3P at the 
autophagosome initiation site. PI3P recruits another protein DFCP1 to start nucleation of 
autophagosome. The third step requires the ATG16L1-ATG5-ATG12 conjugation machinery 
for lipidation of light chain 3-II (LC3-II), which initiates the expansion and also fusion 
between autophagosome and lysosome 
164–166
. 
         Two distinct ubiquitin-like protein conjugation systems are involved in autophagy. The 
first system is ATG5-ATG12 interaction and conjugation, and the second is LC3 processing. 
The first step involves activation of ATG12 by ATG7 (E1 ubiquitin enzyme) through binding 
to its C-terminal glycine in an ATP-dependent manner. After that, the ATG12 protein is 
transferred to ATG10 (an E2 ubiquitin carrier protein) that makes covalent bond of ATG5 to 
ATG12. The ATG5-ATG12 complex then interacts with ATG16 dimer to form a multimeric 
ATG5-ATG12-ATG16 complex that fuses with the newly formed extending phagophore. 
The complex also induces swirl into the growing phagophore through recruitment of 
processed LC3 
159,167
. The second step is similar to the ubiquitin-mediated protein 
degradation systems involved in autophagosome. LC3 is present as full-length cytosolic 
proteins in most cell types. Activation of autophagy, induces proteolytic cleavage of LC3 by 
ATG4, a cysteine protease to generate LC3B-I. The synthesis and processing of LC3 is 
increased after induction of autophagy 
158
. The activation of the PI3K3 or PI3K is required 
for formation of autophagosome, which mainly depends on the formation of a multiprotein 
complex including BECN1 
168
.  
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1.4.2 Role of autophagy in tumorigenesis 
Autophagy can play a dual role in cancer development. Autophagy genes are commonly 
deleted in tumors 
169,170
, leading to increased oxidative stress and DNA damage, which 
subsequently leads to genomic instability and tumor progression 
170–173
. As such, autophagy 
plays a suppressor role. However, autophagy is induced upon cellular stress such as 
starvation, oxidative stress and DNA damage 
174–177
, which protect cancer cells for survival.  
Figure 3. Different stages of autophagosome and autolysosome formation. 
Autophagosome formation starts with activation of the ATG/ULK1 complex, which 
recruits Beclin1 (BECN1) to induce nucleation with VPS34. VPS34 produces 
phosphatidylinositol-3-phosphate (PI3P), which helps to recruit other ATGs and light 
chain 3 (LC3). LC3 activation and phosphorylation leads to conjugation with 
phosphatidylethanolamine (PE). PE acts as a receptor for p62, which binds to 
ubiquitinated proteins and starts degradation once autophagosome fuses with lysosome 
and forms autolysosome. 
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          Autophagy can be suppressed by activation of the PI3K/Akt through activating 
mutations in PI3K, PTEN loss and AKT amplification, which subsequently leads to 
activation of mTOR pathway 
178,179
. Bcl2 amplification and overexpression inhibit autophagy 
through BECN1 
180,181
. Nutrient deprivation or genotoxic stress induces p53 expression, 
which leads to activation of autophagy, due to inhibition of mTOR pathways 
182,183
. p53 can 
suppress autophagy at the basal levels 
184
. Ectopic overexpression of p62 inhibits autophagy 
and leads to tumorigenesis through activation of NF-κB signaling pathway and DNA damage 
response 
170
. Autophagy promotes tumor cell survival under hypoxia or nutrient deprivation 
171
, as well as type II programmed cell death 
185
.  
 
1.5 c-KIT IN CANCER 
Besmer et al first discovered v-KIT in sarcoma virus 
186
, and one year later, cellular c-KIT 
was found by Yarden et al 
187
. c-KIT is a receptor tyrosine kinase (RTK) and a 
transmembrane protein. It contains an extracellular domain, a transmembrane domain and an 
intracellular domain (also called kinase domain since most of the phosphorylation sites are 
present in this domain (Figure 4) 
188
. 
 
            
 c-KIT is expressed in several cell types such as hematopoietic progenitor cells, germ 
cells, melanocytes and mast cells. It plays important roles in organogenesis, development, 
cell differentiation, proliferation, viability and other cellular physiological functions 
189–191
. 
Activation of c-KIT has been observed in several human diseases, including cancer 
192–194
. 
Figure 4. Domain structure of c-KIT. c-KIT is composed of three main domains: (i) The 
extracellular domain, which consists of five immunoglobulin-like domains, three of them 
bind to its ligand stem cell factor (SCF), and the fourth is known to help in dimerization; 
(ii) The transmembrane domain is present in the cell membrane; and (iii) The intracellular 
domain, which contains the tyrosine kinase domain. 
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1.5.1 Activation and function 
In normal cells, c-KIT is activated after binding of its ligand, called stem cell factor (SCF), to 
the extracellular domain of c-KIT. SCF induces homodimerization of the intracellular domain 
or kinase domain of the c-KIT and activates Src-homology2 (SH2), which leads to signal 
transduction (Figure 5) 
190,195
. It can activate several pathways depending on the cellular 
context, including Ras-MAP kinase, PI3K-Akt-mTOR pathways, Ras-Erk pathways, and 
PIP3-dependent PKC pathways 
196,197
. After activation, c-KIT is then ubiquitinated, which 
leads to internalization of the receptor and is then transported into lysosomes for degradation 
190
.  
 
 
 c-KIT overexpression has been found in several human cancers, such as gastrointestinal 
stromal tumor (GIST), mast cell leukemia, testicular germ cell tumors and MCC 
188
. 
Activating mutations of c-KIT are frequently observed in human cancers. Till now around 
500 different types of c-KIT mutations had been reported in human tumors, most of the 
reported mutations are passenger but some of them are also driver mutations 
188
. As an 
example, in GIST, more than 80% of the tumors contain activating mutations of c-KIT 
193
. 
Figure 5. Activation and function of c-KIT. Once stem cell factor (SCF) binds to 
extracellular ligand binding domain of c-KIT, the dimerization domain is activated and 
starts dimerization, leading to activation of the kinase domain by phosphorylation. Its 
signal is then transferred to the nucleus to perform its functions.  
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These mutations lead to ligand-independent activation of c-KIT 
198–200
, which activates PI3K-
Akt, STATs and Erk-MAP kinase pathways that promote GIST development 
201,202
. 
1.5.2 Paranuclear c-KIT dot in cancers 
 As aforementioned, c-KIT is generally expressed on the plasma membrane, where it is 
activated after binding with its ligand SCF, leading to activation of signaling cascade. 
However, c-KIT is also present as paranuclear dot-like structure in some cancer types, such 
as GIST, mast cell leukemia and testicular germ cell tumor 
203–205
. For GIST and mast cell 
leukemia, it is now known that mutations of the c-KIT gene contribute to the paranuclear 
localization 
204,206
. However, the exact subcellular localization of paranuclear c-KIT is 
different between GIST and mast cell leukemia. 
          In GIST, paranuclear c-KIT is mainly localized on Golgi apparatus 
205
. The aberrant 
kinase activity of mutant c-KIT prevents its transport from the Golgi to the plasma membrane 
205
 and PKC-Φ promotes stabilization of the mutant c-KIT in the Golgi complex 207. In mast 
cell leukemia, c-KIT is mainly localized on endolysosome and endoplasmic reticulum (ER) 
204,208,209
. Similar to GIST, the kinase activity of mutant c-KIT is required for the 
accumulation of mutant c-KIT on endolysosomes via clathrin-mediated endocytosis 
210
. 
Despite their different localizations, they share common oncogenic signaling; mutant c-KIT 
activates the PI3K-Akt pathway in both cancer types 
205,210
. Besides PI3K-Akt pathway, 
mutant c-KIT can also activate STAT5 and Erk in GIST 
205
. On other hand, in mast cell 
leukemia, mutant c-KIT activates STAT5 on the ER 
210
. 
 
1.6 ENERGY METABOLISM 
Energy metabolism is defined as the process that produces energy for performing all kind of 
cellular functions in living organisms. There are several processes or pathways in the cells to 
generate energy including glycolysis, tricarboxylic acid (TCA) cycle, pentose phosphate 
pathways and mitochondrial respiration. These are the major metabolic pathways in the cells 
to fulfill their energy requirement and maintain cellular homeostasis.  
1.6.1 Glycolysis and mitochondrial metabolism 
Glycolysis and mitochondrial energy metabolisms are the most commonly used processes to 
generate energy in the cells 
211,212
. Glycolysis is a process by which glucose molecules are 
catalyzed by several enzymes and produce, pyruvate, 2 molecules of ATP and NADH each. It 
is a universal process used by almost all cells 
213
. If cells are hypoxic, pyruvate is then 
converted into lactate 
214
. In normal cells, pyruvate is converted into acetyl-coA, which 
enters the TCA cycles and is further catalysed by a series of enzymatic reactions to produce 
ATP, NADH and FADH2 as energy intermediates, and releasing CO2 and H2O as side 
products. The FADH2 and NADH produced from the TCA are then transported to the 
electron transport chain and produce ATP with the help of proton gradient through 
respiratory complexes I, II, III, and IV 
215–218
. Mitochondria also regulate the energy 
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demand and supply balance by increasing the number of mitochondria whenever they are 
needed or decreasing the number of mitochondria through fission and mitophagy when the 
energy demand is less 
217,219,220
. 
1.6.2 Metabolic reprogramming in cancer  
Metabolic reprogramming is a hallmark of cancer cells 
221
. In general, normal cells mostly 
rely on mitochondrial oxidative phosphorylation to produce energy to support their 
activities. However, most cancer cells depend on aerobic glycolysis to generate energy 
sources to support tumor growth 
214,222,223
 (Figure 6).  
 
 
           It is now known that several mechanisms can lead to metabolic reprogramming from 
oxidative phosphorylation to glycolysis in cancer cells. Among them, overexpression of 
glycolytic enzymes, such as GLUT1, HKII and LDHA, is frequently observed in various 
cancer cells 
224,225
. Lactate dehydrogenases (LDHs) play an important role in the 
interconversion of pyruvate and lactate. LDHB is responsible for converting lactate to 
pyruvate that fuels the TCA, while LDHA converts pyruvate to lactate. The balance between 
Figure 6. Energy metabolism in normal and tumor cells. Normal cells generally use 
mitochondrial respiration as a major process to produce energy. In this process glucose is 
converted into pyruvate by several enzymatic cascades to produce two ATP molecules. 
The pyruvate is further converted into acetyl-CoA and transported into tricarboxylic acid 
(TCA) cycle, which produces FADH2 and NADH. These molecules are further reduced 
in the electron transport chain to produce 32 molecules of ATP. Excessive pyruvate is 
then converted into lactate, by lactate dehydrogenase enzyme. Unlike normal cells, tumor 
cells preferentially use aerobic glycolysis and lactate as a major source of energy. This 
process is also called Warburg effect. 
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these two enzymatic activities can affect lactate homeostasis in the cells, which can switch 
between glycolysis and oxidative phosphorylation. Deregulations of these enzymes can lead 
to metabolic reprogramming, which has been observed in several cancer types, such as 
pancreatic cancer and lymphoma 
226,227
. Additionally, lactate homeostasis also requires 
monocarboxylic acid transporters (MCTs) that control the excessive levels of lactate in the 
cells by transporting the lactate across the plasma membrane. High levels of these 
transporters have also been observed in several tumor types, including breast cancer, 
choriocarcinoma and head and neck cancer 
228–230
.  
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2    AIMS OF THE STUDY 
 
The overall aim of this thesis work was to investigate the functional roles of MCPyV T-
antigens in MCC tumorigenesis. The specific aims of the thesis were to: 
 
• Determine the involvement of MCPyV T-antigens in regulation of miRNAs and autophagy 
(Paper I) 
 
• Investigate the expression and function of c-KIT in MCC (Paper II) 
 
• Characterize the functional role of miR-375 and its target LDHB in MCPyV+ and MCPyV- 
MCC cells (Paper III) 
 
• Study the role of MCPyV T-antigens in regulation of LDHB expression and glycolysis 
(Paper IV) 
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3 MATERIALS AND METHODS 
3.1 CELL LINES AND MCC PRIMARY CULTURE 
Eight human established cell lines and one primary culture (ME27) were included in this 
thesis, which are listed in Table 3. 
 
The authenticity of the six MCC cell lines and GIST882 had been confirmed by genotyping 
of short tandem repeat (STR), as shown in Table 4. 
 
Table 3. Human cell lines and primary culture used in this thesis
Name Description
MCPyV 
status Source Paper
MCC13 Merkel cell carcinoma negative Cell Bank Australia, Westmead, NSW, 
Australia I-IV
MCC14/2 Merkel cell carcinoma negative Cell Bank Australia, Westmead, NSW, 
Australia I-IV
MCC26 Merkel cell carcinoma negative Cell Bank Australia, Westmead, NSW, 
Australia I-III
WaGa Merkel cell carcinoma positive Gift from Dr. JC Becker (Medical 
University of Graz, Austria) I-IV
MKL-1 Merkel cell carcinoma positive Gift from Dr. NL Krett (Nortwestern 
University, IL, USA) I-IV
MKL-2 Merkel cell carcinoma positive
Gift from Dr. Roland Houben (University 
Hospital Würzburg, Germany) II, III
ME27 Merkel cell carcinoma positive Shi et al., unpublished II
GIST882 Gastrointestinal stromal tumor n.a. Gift from Dr. JA Fletcher (Brigham and 
Women's hospital, Boston, MA) II
HEK293 Human embryonic kidney n.a. Gift from Dr. Yingbo Lin (Karolinska 
Institutet, Sweden) II
n.a.=not analyzed
Table 4. Short tandem repeat (STR) profiles of the 6 MCC cell lines and GIST882 used in this thesis
Locus MCC13 MCC14/2 MCC26 WaGa MKL-1 MKL-2 GIST882
D8S1179 13, 14 10, 14 8, 10 10, 13 10, 10 11, 13 12, 12
D21S11 30, 31 29, 32.2 31, 32.2 28, 30 30, 30 31.2, 31.2 29, 31.2
D7S820 10, 10 8, 10 8, 9 10, 10 8, 11 10, 13 10, 15
CSF1PO 12, 12 10, 11 10, 11 12, 12 11, 12 10, 12 11, 11
D3S1358 16, 18 16, 16 17, 17 14, 14 16, 16 17, 17 15, 15
THO1 7, 9.3 6, 9.3 9.3, 9.3 9.3, 9.3 9, 9.3 7, 8 9, 9
D13S317 12, 12 13, 13 13, 14 8, 13 8, 11 12, 13 12, 12
D16S539 9, 11 13, 13 11, 13 11, 12 10, 12 10, 12 11, 11
D2S1338 19, 20 19, 19 23, 26 20, 23 17, 17 17, 23 18, 26
D19S433 15, 15 12, 14 16, 16 14, 16 14.2, 15.2 13.2, 14 13, 15
vWA 17, 17 17, 18 16, 18 16, 17 16, 18 16, 17 16, 17
TPOX 8, 8 8, 8 8, 8 8, 11 8, 8 8, 11 11, 11
D18S51 16, 17 15, 17 15, 18 10, 13 12, 18 14, 17 14, 14
AMEL X, X X, X X, X X, Y X, Y X, Y X, Y
D5S818 9, 12 13, 13 12, 12 12, 12 11, 12 12, 14 12, 12
FGA 19, 20 21, 21 24, 25 19, 19 21, 25 19, 26 23, 23
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3.2 MCC TUMOR SAMPLES 
Forty-five formalin-fixed paraffin-embedded and 28 frozen MCC tumor samples were 
collected at Karolinska University Hospital or Stockholm South General Hospital. The 
diagnosis of MCC was established at the time of diagnosis by routine histopathological and 
immunohistochemical analyses. Forty-five FFPE samples were used in Paper I, 45 FFPE 
sections in Paper II and 28 frozen and 26 FFPE samples were used in Paper III. The clinical 
information of the patients is described in their respective studies. 
 
3.3 RNA EXTRACTION AND RT-QPCR 
3.3.1  RNA extraction 
Total RNA was isolated by using mirVana miRNA isolation kit (Ambion/Thermo Fisher 
Scientific, Waltham, MA) and the concentrations were measured with a NanoDrop 
spectrophotometer (NanoDrop technologies, Wilmington, DE).  
3.3.2  Reverse transcription-quantitative polymerase chain reaction (RT-
qPCR) 
RT-qPCR is a reliable method used to detect and measure transcripts in a particular sample 
through PCR.  There are two types of RT-qPCR methods: SYBR green and TaqMan assays. 
SYBR green is a relative cost effective and easy method to quantify target gene expression. It 
contains fluorescent dye that binds to dsDNA molecules. The amount of fluorescence 
measured at the end of each PCR cycle reflects the quantity of the amplified cDNA. This 
method was used to quantify mRNA expression of MCPyV T-antigens (Paper I).  
           The TaqMan assay requires specific primers and TaqMan probes. TaqMan probe is a 
sequence-specific DNA molecule with a fluorophore attached at the 5´-end and a quencher at 
the 3´-end. When the fluorophore and quencher are in close proximity it inhibits the 
fluorescence signal. During PCR amplification, the Taq DNA polymerase extends the primer 
and cleaves the TaqMan probe through its 5´-to 3´exonuclease activity. After cleaving the 
probe, the fluorophore is released from the quencher emitting a fluorescence signal for 
detection and quantification. This method was performed to detect miR-375, miR-30a-3p, 
miR-30a-5p, miR-125a-3p, miR-16, pri-miR-375, pri-miR-30a, 18S rRNA and RNU6B in 
Paper I, miR-375, LDHB, RNU6B and GAPDH in Paper III, and LDHB and β-actin in 
Paper IV. All TaqMan assays were purchased from Applied Biosystems/Thermo Fisher 
Scientific (Foster City, CA). 
 
3.4 PLASMIDS 
Plasmid is a small circular dsDNA molecule that has the capacity to replicate independently 
from chromosomal DNA. It is widely used as a vector to transfer, multiply or express specific 
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gene(s) of interest. In this thesis, different plasmids were used to express MCPyV T-antigens, 
short-hairpin RNA (shRNA) targeting MCPyV T-antigens, miRNAs, miRNA sponges, 
cellular protein-coding genes and reporters. 
3.4.1  MCPyV T-antigens expression plasmids 
Five different MCPyV T-antigens expression vectors were used (Figure 7). LTco and sTco 
are codon-optimized vectors with deleted splicing donor and acceptor sites in the sequence, 
therefore they only express LT or sT, respectively. LT339 contains tumor-derived LT cDNA 
isolated from a MCC tumor, which encodes a truncated LT with 469 aa. Additionally, two 
LT mutants were also applied. LTco
D44N
 expresses a full-length LT with a substitution 
mutation at residue 44 (D>N) in the HSC70 binding domain, which abolishes the interaction 
between HSC70 and LT. LT339W209A encodes a truncated LT with substitution of tryptophan 
for alanine at residue 209, disrupting the interaction between LT and VAM6P. 
 
 
3.4.2  Cellular protein-coding plasmids 
In Paper II, pcDNA3-KIT-WT expressing full-length coding sequence of c-KIT was kindly 
provided by Dr. Lars Rönnstrand (Lund University), and in Paper IV, LDHB-FLAG plasmid 
expressing full-length coding sequence of LDHB and DYKDDDDK(FLAG)-tagged on its 
carboxyl terminus was purchased from GenScript (Piscataway, NJ). 
 
Wild-type LT (LTco) 
Small T (sTco) 
Truncated LT (LT339) 
shTA shsTA 
OBD MUR DnaJ 
Core helicase/ATPase MUR DnaJ OBD 
DnaJ unique 
469 aa 
817 aa 
186 aa 
HSC70  
binding 
LTcoD44N Core helicase/ATPase MUR DnaJ OBD 817 aa 
VAM6P 
binding 
LT339W209A OBD MUR DnaJ 469 aa 
W209A 
D44N 
Figure 7. Plasmids expressing different MCPyV T-antigens and short-hairpin RNAs 
targeting T-antigens. LTco and LT339 express wild-type and truncated LT, 
respectively. sTco expresses only small T. LTco
D44N 
has a substitution mutation of 
aspartic acid at residue 44 with asparagine, while the LT339W209A has alanine 
substituted for tryptophan at residue 209. shTA is a short hairpin RNA targeting the 
common exon 1 of both LT and sT, and shsTA only targets the unique region of sT. 
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3.4.3  Short hairpin RNA (shRNA), miRNA expression and sponges 
shRNA vector is used to express a single-stranded RNA molecule with a hairpin structure, 
which can be used to silence a particular target gene by RNA interference (RNAi). Generally, 
shRNAs targeting specific genes of interest consist of sense and antisense sequences 
separated by a loop sequence, which folds back into a loop structure after being transcribed. 
This hairpin transcript is then exported to the cytoplasm and processed by DICER enzyme 
into ~21-nucleotide small interfering RNA (siRNA) duplexes that are loaded into RISC for 
gene silencing. In this thesis, shRNAs targeting MCPyV LT and/or sT were performed using 
shTA and shsTA, respectively (Papers I and IV). In Paper II, two shRNAs targeting 
common exon 1 of MCPyV T-antigens were used: shTA1 and shTA2. shTA2 targets the 
5’UTR of LT/sT at nucleotide 173-193, while shTA1 (same as shTA in Papers I and IV) 
targets the nucleotide sequence 222-242 encoding the DnaJ domain of T-antigens (Figure 7). 
In Paper II, shRNA targeting exon 7 of KIT was also constructed to silence c-KIT 
expression. 
          miRNA expression vectors are similar to shRNAs, which express RNA transcripts with 
a loop structure. There are two ways to construct miRNA expression vectors. One way is to 
clone a specific mature miRNA sequence together with its respective complementary 
sequence and the loop sequence into a vector. Another way is to amplify or synthesize the 
precursor sequence of specific miRNA (that is known to have a natural hairpin structure after 
being transcribed) and clone it into a vector. Examples of these designs are illustrated in 
Supporting Information, Fig. S2 of Paper I. 
         miRNAs sponge vectors express RNA transcripts that contain multiple miRNA binding 
sites, which can sequester miRNAs from their endogenous targets, thereby inhibiting miRNA 
function. Description of miRNA sponge vectors for miR-375sp, miR-30a-3psp and miR-30a-
5psp is given in Supporting Information, Fig. S1 of Paper I. 
3.4.4  Reporter constructs 
Two types of reporter constructs, mRFP-GFP-LC3 and luciferase reporters, were used in 
Paper I. The mRFP-GFP-LC3 reporter plasmid was used to detect autophagic flux. It is 
based on the concept of acidic lysosomal pH that quenches the GFP signal in autophagic 
substrate, which allows us to distinguish autolysosomes and autophagosomes. 
Autophagosomes are represented by yellow puncta (RFP+/GFP+), and autolysosomes are 
shown in red puncta (RFP+/GFP-). If both yellow and red puncta are increased, it indicates 
an increase of autophagic flux. If only yellow puncta are increased, it indicates that 
autophagic degradation is blocked.  
           Luciferase is a bioluminescence-producing enzyme commonly found in fireflies. This 
enzyme can react with a luminescent substrate, luciferin, to produce light emission. There are 
two commonly used luciferases: firefly and Renilla that generate light in the range of 550-570 
nm and 480 nm, respectively. Typically, a luciferase gene is cloned upstream or downstream 
of a specific DNA sequence of interest that allows us to quantify the activity of the target 
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sequence by measuring the released light. In Paper I, luciferase reporters were used to verify 
specific miRNA binding sites and to determine the efficiency of miRNA sponges. 
 
3.5 TRANSFECTION 
Transfection is the most widely used method to introduce external DNA or RNA into the 
eukaryotic cells. This method is mainly based on opening the pores into the membrane by 
different mechanisms and delivers the external nucleic acid into the cells. In this thesis lipid 
based transfection and nucleofection were used. 
3.5.1  Lipid-based transfection 
Lipid based transfection is based on different charges between the lipid-based reagent and the 
nucleic acid. The positively charged head group of lipid reagents forms a complex with the 
negatively charged nucleic acid called liposome. The liposome then fuses with the cell 
membrane and delivers the nucleic acid into the cells by endocytosis. In this thesis 
Lipofectamine 2000 was used for transfection of plasmid DNAs and/or siRNAs (Papers I-
IV). RNAiMAX was used to deliver miRNA mimics into the cells (Paper III). miRNA 
mimics are small chemically modified dsRNA molecules that mimic endogenous mature 
miRNAs. This transfection method was used for all, except MCPyV+, cell lines. 
3.5.2  Nucleofection 
For all MCPyV+ cell lines (Papers I-IV), nucleofection was used. This method is based on 
electroporation, which uses a combination of cell-type specific solutions and specific voltage 
parameters to deliver nucleic acid directly into the nucleus of the cells. This method is 
suitable for primary cell cultures, non-dividing cells and cell lines that have been difficult to 
transfect by lipid-based methods.  
 
3.6 PROTEIN EXPRESSION AND MODIFICATION ANALYSES 
3.6.1  Western blot 
Western blot, also called immunoblot, is the most commonly used molecular biology 
technique to detect, quantify and identify specific proteins based on their respective 
molecular weight using a specific antibody. The first step of this method is to extract protein 
lysates from cells or tissue samples using lysis buffer. Subsequently the protein lysate is 
loaded onto an electrophoresis gel to separate proteins based on their respective sizes. The 
proteins are then transferred to a nitrocellulose or polyvinylidene fluoride membrane, and 
incubated with specific antibodies to the target proteins. After that, washing buffer is used to 
remove unbound or non-specific primary antibodies from the membrane, followed by 
incubation with species-specific horseradish peroxidase (HRP) or fluorescent-conjugated 
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secondary antibody. The results can be detected by chemiluminescence or fluorescence 
(depending on the type of secondary antibody) using an imaging system. 
            Besides detection and quantification of specific proteins, Western blot can also be 
used to detect protein modifications. Protein modification or posttranslational modification of 
proteins may occur after protein synthesis. There are several types of modification, mostly 
performed by catalytic enzymes that recognize a specific target sequence or amino acid of the 
specific proteins. The most common modifications are phosphorylation, acetylation, 
methylation and glycosylation. In Paper II, phosphorylation and glycosylation of c-KIT were 
analyzed. Protein phosphorylation is a post-translational modification of proteins where a 
phosphate is covalently bound to an amino acid residue by a protein kinase. Glycosylation is 
the modification where a carbohydrate is added to a protein. To detect the phosphorylation 
state of c-KIT, a phospho-specific antibody was used to recognize the phosphorylated amino 
acid. To assess the glycosylation status of c-KIT, two glycosidases (endonuclease H and 
peptide:N-glycosidase F) were used to digest high mannose or complex glycan structures, 
followed by detection of deglycosylated c-KIT using Western blotting. 
3.6.2   Immunohistochemistry 
Immunohistochemistry is widely used to identify expression levels, tissue distribution and 
subcellular localization of specific proteins on tissue sections. This method also requires 
specific antibody to recognize specific antigen in tissue samples, followed by detection of the 
antibody-antigen interaction using a secondary antibody conjugated with an enzyme or a 
fluorophore. This method has been applied to detect MCPyV LT, p62 and ATG7 in Paper I, 
and c-KIT in Paper II. 
 
3.7 PROTEIN-PROTEIN INTERACTION 
Protein-protein interactions play an important role in predicting the functions of specific 
target proteins. These interactions control a range of biological functions such as metabolic 
processes, cell-to-cell interactions and development. Around 80% of the proteins work in a 
group or cluster to perform their functions. There are several methods to identify these 
interactions. Two of them were used in this thesis, as described below: 
3.7.1  Co-immunoprecipitation 
Co-immunoprecipitation (co-IP) is a very popular technique to capture the primary target (i.e. 
antigen) and other proteins that are bound to the target in a protein lysate. Typically, the 
target protein and its associated protein complex are pulled down using immobilized antibody 
on beads. The isolated protein complexes are then separated and detected by Western 
blotting. Besides co-IP, co-localization of two proteins can also be assessed using 
immunofluorescence microscopy, as described below. 
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3.7.2   Immunofluorescence confocal microscopy 
Immunofluorescence (IF) microscopy is a robust and reliable technique to assess expression 
and subcellular localization of a target protein. This technique can be used on cultured cells, 
single cell, and tissue sections. In Paper II, IF was used to detect the expression and 
subcellular localization of c-KIT. In addition, the interaction between c-KIT and BECN1 was 
also analyzed by co-localization of the two proteins using IF and confocal microscopy. 
 
3.8 AUTOPHAGY ASSAYS 
Autophagy is a dynamic process and multiple assays are recommended to verify an 
autophagic response. In this thesis, three different methods were applied to study the effect on 
autophagy.  
3.8.1  Western blot detection of LC3-II 
The LC3 protein is known to be present in all autophagic membranes from an early stage (i.e. 
phagophore) to a late stage (i.e. autolysosome). The total amount of LC3 is a good indicator 
of the autophagy index. Full-length LC3 is first cleaved by the ATG4 autophagy protein 
forming the cytoplasmic LC3-I. LC3-I is then conjugated with phosphatidylethanolamine by 
ATG7 and ATG3 to form LC3-II. Progression of autophagy can be detected by LC3-I to 
LC3-II conversion. Detection of LC3-II expression levels at a specific time point is not 
sufficient to estimate the actual autophagy flux because of its dynamic nature. Increased LC3-
II expression levels can either reflect induction of autophagy or inhibition of autolysosme 
formation. To detect actual induction or inhibition of LC3-II levels, autolysosome formation 
can be blocked by specific chemical. In this thesis bafilomycin A was used to block 
autolysosome formation and then detection of the LC3-II level was evaluated with and 
without the treatment.  
3.8.2  mRFP-GFP-LC3 reporter  
Another method to evaluate autophagy flux is to measure the LC3 puncta from the mRFP-
GFP-LC3 reporter by using confocal microscopy. These puncta correspond to the number of 
autophagosomes or autolysosomes (refer to Chapter 3.3.4). The principle of this reporter and 
the interpretation of the fluorescent puncta had been described in Chapter 3.3.4. 
3.8.3  Transmission electron microscopy (TEM) 
TEM is a powerful technique to study the ultrastructure of cells based on the image generated 
from a high-energy beam that passes through a very thin tissue section. This method is an 
important tool to identify autophagic vesicles in cells; however it may not be readily 
quantifiable. The LC3 immunoblot and reporter assays are more quantitative approaches for 
monitoring autophagy.  
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3.9 CELL VIABILITY OR GROWTH ASSAYS 
Trypan blue exclusion and WST-1 assays were used to assess cell viability or cell growth in 
this thesis. These assays are briefly described in the following sections: 
3.9.1  Trypan blue exclusion assay 
The trypan blue assay is based on the principle that live cells possess a rigid and intact plasma 
membrane that prevents entry of trypan blue dye, whereas dead cells are not able to prevent 
the entry of the trypan blue dye. Dead and live cells can be distinguished and quantified using 
a bright field microscope or an automatic cell counter. This method was used to measure the 
number of live and dead cells after treatment with bafilomycin A1, torin-1, pan-caspase 
inhibitor (z-VAD-FMK) or camptothecin (Paper I). This assay was also used to assess the 
effect of miR-375 and LDHB regulation on cell growth in MCC cell lines (Paper III). 
3.9.2  WST-1 assay 
WST-1 is a colorimetric based assay used for quantification of cell proliferation and viability.  
The principle of this assay is based on the conversion of tetrazolium salt WST-1 into a 
colored compound by dehydrogenase enzymes, which are produced by mitochondria. The 
amount of colored product in the medium is directly proportional to the amount of enzymes 
produced by the mitochondria; as a result it corresponds to the number of metabolic active 
cells. This method was used as the primary method for assessment of cell growth or viability 
in Papers I-IV. 
 
3.10 APOPTOSIS ASSAYS 
Apoptosis is a form of cell death, which plays an essential role to maintain homeostasis and 
in the development of organisms. Apoptosis can be induced by several external and internal 
factors like UV-radiation, DNA damaging chemicals or any kind of stress inside the cells. 
Apoptotic cells generally display morphological changes (e.g. membrane blebbing, nuclear 
fragmentation and chromatin condensation) and biochemical modifications (e.g. protein 
cleavage, DNA breakage). These features are used in the following methods to detect 
apoptosis. 
3.10.1  Annexin V assay 
Annexin V has a strong affinity binding specifically to phosphatidylserine (PS). When 
apoptosis is activated, changes occur in the membrane structure of the apoptotic cells causing 
PS flips from the inner to the outer membrane surface. This allows the binding of Annexin V 
to PS of the apoptotic cells. Typically, Annexin V is conjugated with a fluorophore that 
allows the detection using flow cytometry. Propidium iodide (PI) staining is also commonly 
used together with the annexin V detection. This stain does not stain viable cells or early 
apoptotic cells because of an intact plasma membrane, thus enables to distinguish late 
apoptotic cells from early apoptotic cells. This method was applied in Papers I, III and IV. 
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3.10.2  Cleaved PARP 
Poly (ADP-ribose) polymerase-1 (PARP-1) is a nuclear protein physiologically involved in 
DNA repair mechanism by adding poly (ADP ribose) polymers in response to several types 
of cellular stresses. During apoptosis, the full-length PARP-1 (116 kDa) is cleaved by 
caspases to generate two fragments: 89 kDa and 24 kDa. The 89 kDa carboxyl-terminal 
fragments containing the catalytic domain has reduced DNA binding capacity and is released 
to the cytosol, while the 24 kDa fragment irreversibly binds to nicked DNA and inhibits DNA 
repair. These PARP-1 cleavage products can be detected by Western blotting using specific 
antibodies targeting these fragments, which had been applied in Papers II and III. 
 
3.11 METABOLIC ASSAYS 
Energy metabolism is the process of energy production from nutrients, which is required to 
maintain cellular homeostasis in the presence or absence of oxygen. Generally, normal cells 
rely primarily on mitochondrial respiration to generate energy and cancer cells preferentially 
use glycolysis. In this thesis, two metabolic assays were used to measure extracellular oxygen 
consumption and acid production, which monitor rates of glycolysis and respiration (Paper 
IV). 
3.11.1  Extracellular Acidification Rate (ECAR) 
Glycolysis is a catabolic metabolic process, which provides energy to the cells to maintain 
their growth, viability and perform all other functions for their survival. In glycolysis, glucose 
is converted to lactate and protons. As lactate is the source for glycolytic acidification, 
glycolytic activities can be measured by calculating the rates of extracellular acidification. 
This assay is based on the pH-sensitive reagent. This reagent is chemically stable and inert. 
When acidification is increased, it increases the signal for detection. 
3.11.2  Oxygen Consumption Rate (OCR) 
The second major pathway for cells to provide energy is oxidative phosphorylation. 
Oxidative phosphorylation uses tricarboxylic acid cycle (TCA), which requires the electron 
transport chain in the mitochondria using oxygen as a terminal electron acceptor. The Abcam 
extracellular oxygen consumption reagent is an oxygen-sensitive fluorescent dye, which 
measures the amount of oxygen in the assay medium. Normally, the dye is quenched by 
oxygen. During mitochondrial respiration, oxygen is depleted, which reduces the quenching 
of the fluorescent dye that leads to an increase of the fluorescence signal. 
 
3.12 STATISTICAL ANALYSES 
Student’s paired t-test was used to compare two groups in transfection experiments (Papers 
I-IV). Multiple comparisons were evaluated using One-way ANOVA with post-hoc Tukey 
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test (Paper I) or Dunnett’s test (Paper II). Associations of immunohistochemical staining 
and MCPyV status were assessed using Fisher’s exact text (Paper I), while correlation 
between miR-375 and LDHB expressions was evaluated using Spearman’s rank order 
correlation (Paper III). All analyses were two-tailed and p-values <0.05 were considered as 
significant. 
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4 RESULTS AND DISCUSSIONS 
4.1 INVOLVEMENT OF MCPYV T-ANTIGENS IN MIRNAS AND AUTOPHAGY 
REGULATION (PAPER I) 
In our previous study, we identified a subset of miRNAs associated with MCPyV status in 
MCC clinical samples 
150
. Two of these MCPyV-associated miRNAs (miR-375 and miR-30a-
5p) are known to target autophagy genes 
231–233
. We therefore investigated whether MCPyV 
T-antigens could regulate these specific miRNAs and autophagy.  
4.1.1 MCPyV T-antigens regulate miRNAs through the DnaJ domain of T-
antigen 
We first determined whether MCPyV T-antigens could regulate specific miRNA expression. 
Here, we had chosen to analyse three MCPyV-associated miRNAs, i.e. miR-375, miR-30a-3p 
and miR-30a-5p, identified from our previous study. Indeed, silencing of MCPyV LT and/or 
sT in MCPyV+ MCC cell lines decreased levels of miR-375, miR-30a-3p and miR-30a-5p. 
Concordantly, ectopic expression of MCPyV sT, full-length or truncated LT in MCPyV- 
MCC cell lines increased the expressions of these miRNAs. To demonstrate the specificity of 
the results, we also included two non-MCPyV-associated miRNAs (miR-125a-3p and miR-
16), which did not show significant changes upon modulation of MCPyV T-antigen 
expressions. We further showed that silencing of LT and/or sT had no effect on the primary 
transcripts of miR-375 and miR-30a, excluding the effect at transcriptional levels. On the 
other hand, silencing of LT and/or sT reduced the stability of these mature miRNAs, 
suggesting that the viral T-antigens regulate these miRNAs at post-transcriptional level. 
          We next sought to identify which domain of the viral T-antigens is required for miRNA 
regulation. We focused on the DnaJ domain because it is shared between the LT and sT. Here 
we applied a mutant in the DnaJ domain, D44N, and compared the effect with its wild-type. 
Our results revealed that the DnaJ mutant completely abolished the LT-induced miRNA 
expressions. Further investigations are now being performed to address the mechanism how 
MCPyV T-antigens regulate these miRNAs through the DnaJ domain. 
4.1.2 MCPyV-regulated miRNAs targets multiple autophagy genes  
miR-375 and miR-30a-5p are known to suppress ATG7 and BECN1, respectively 
231,232
. Here, 
we showed that these two miRNAs could also target these autophagy genes and suppress 
autophagy in MCC cell lines. Additionally, we discovered that miR-375 could also target the 
autophagic receptor SQSTM1 (also known as p62), which binds directly to LC3 to facilitate 
autophagic degradation. Similarly, we also observed that, besides miR-30a-5p, miR-30a-3p 
also regulates BECN1 expression. Using a computational approach, we identified a putative 
target site in the coding sequence of SQSTM1 and BECN1. Further experiments validated the 
direct interactions between miR-375 and SQSTM1, as well as between miR-30a-3p and 
BECN1, using luciferase reporter assays. miR-30a-3p was also verified to regulate autophagy 
using Western blot analysis of LC3-II and mRFP-GFP-LC3 reporter assays. 
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4.1.3 MCPyV sT and truncated LT regulate autophagy 
Given that these three miRNAs were regulated by MCPyV T-antigens, we investigated 
whether MCPyV T-antigens could also regulate autophagy. Indeed, our results showed that 
silencing of MCPyV LT and/or sT in MCPyV+ cell lines increased LC3-II levels in the 
presence or absence of bafilomycin A1 by Western blotting, as well as the number of 
autophagosomes and autolysosomes by LC3 fluorescence reporter assay and transmission 
electron microscopy. Concordantly, ectopic expression of truncated LT and sT could 
suppress autophagy in MCPyV- MCC cell lines; however the wild-type LT did not have 
significant effect on autophagy. One plausible explanation for this effect is that the carboxyl-
terminal of wild-type LT can induce autophagy by DNA damage response that counteracts 
the autophagy suppression effect. 
           To evaluate the clinical significance of our findings, we evaluated 
immunohistochemical staining of ATG7 and p62 in 45 MCC tumors. Our results revealed 
that both ATG7 and p62 expressions were lower in MCPyV+ than MCPyV- MCC tumors, 
suggesting the involvement of MCPyV oncoproteins in regulation of autophagy genes that 
leads to autophagy suppression. However, the viral oncoproteins can also suppress autophagy 
through other mechanisms, such as c-KIT in Paper II. 
4.1.4 Inhibition of autophagy rescues cell death induced by Torin-1  
Here, we hypothesized that suppression of autophagy could protect MCC cells from cell 
death in MCPyV + MCC cells. To address this question, we evaluated the effect on viability 
in cells treated with Torin-1 (an mTOR inhibitor) or a combination of Torin-1 and 
bafilomycin A1 (autophagy inhibitor) or z-VAD-FMK (pan-caspase inhibitor). Using WST-1 
and Annexin V assays, we showed that inhibition of autophagy could rescue cell death 
induced by Torin-1, however inhibition of caspases could not rescue cell death.  The results 
suggest that suppression of autophagy is important for MCC cell survival.  
          In summary, we describe a network that MCPyV oncoproteins and their-regulated 
miRNAs can hijack the autophagy machinery in MCC by directly targeting multiple 
autophagy genes. Suppression of autophagy could protect MCC cell survival. Our findings 
may shed light on a potential therapeutic strategy for this aggressive disease. 
 
4.2 EXPRESSION AND FUNCTION OF C-KIT IN MCPYV+ MCC (PAPER II) 
c-KIT is a receptor tyrosine kinase that is commonly overexpressed and activated in cancer 
193,234
. Similar to other tumor types, c-KIT overexpression has been reported in MCC and is 
associated with poor prognosis 
235
. However its functional role in MCC is yet to be 
determined. 
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4.2.1 MCPyV truncated LT induces paranuclear retention of c-KIT 
We first investigated c-KIT expression in both MCPyV+ and MCPyV– MCC cell lines using 
immunofluorescence. Unexpectedly, we observed paranuclear dot-like staining of c-KIT in 
all three MCPyV+ MCC cell lines, but its expression was barely detectable in all three 
MCPyV- MCC cell lines. Similarly, the paranuclear dot-like staining was also more 
commonly observed in MCPyV+ than MCPyV- MCC tumors; On the other hand, 
membranous staining of c-KIT was more common in MCPyV- MCC tumors. 
          We then assessed whether MCPyV T-antigens play a role in paranuclear localization of 
c-KIT. Indeed, when we silenced MCPyV T-antigens in the MCPyV+ WaGa cells, the 
number of cells with paranuclear c-KIT dot structure was markedly reduced. On the other 
hand, we observed an increase number of cells with cytoplasmic distribution of c-KIT. To 
further evaluate which viral T-antigen(s) contribute to the paranuclear c-KIT dot, we 
ectopically co-expressed c-KIT and MCPyV sT, wild-type or truncated LT. The results 
showed that only the truncated LT could recapitulate the paranuclear dot of c-KIT. The LT is 
known to interact with Vam6p 
62
, which is involved in lysosome trafficking 
236
. We therefore 
hypothesized that the interaction between LT and Vam6p results in paranuclear retention of 
c-KIT. Using the W209A mutant of LT339 (which is defective in Vam6p interaction), the 
paranuclear retention of c-KIT was abolished. 
           The next question was to address the subcellular localization of c-KIT. Using 
immunofluorescence, our results showed that the paranuclear c-KIT was partially overlapped 
with the Golgi marker (GOLGB1). As c-KIT proteins undergo a series of glycosylations, we 
assessed the glycosylation status of c-KIT in MCPyV+ MCC cells. The results revealed that 
c-KIT proteins in the MCPyV+ cell lines were mainly in the mature form (145 kDa) and 
complex glycosylated, as evidenced by digestion with the PNGase F but not with the endo H. 
Furthermore, we observed that all three MCPyV+ MCC cell lines had detectable level of 
phospho-KIT, as detected by immunoblotting. These results suggest that the complex 
glycosylated c-KIT has been transported to the plasma membrane and activated by its ligand, 
SCF. We therefore hypothesize that the endocytosed c-KIT is likely blocked from 
degradation by the LT-Vam6p interaction, leading to stabilization of c-KIT in the paranuclear 
compartment. In line with our hypothesis, using immunoblotting, we observed an 
accumulation of c-KIT in the truncated LT-expressing cells and very low c-KIT expression in 
cells expressing sT or full-length LT. Ongoing experiments are conducted to address whether 
c-KIT is accumulated on the Golgi from the early secretory or endocytic pathways. 
4.2.2 c-KIT interacts with BECN1 in MCPyV+ MCC cell lines 
In Paper I, we have shown that MCPyV truncated LT can inhibit autophagy and another 
tyrosine kinase receptor, epidermal growth factor (EGFR), has been demonstrated to suppress 
autophagy through BECN1 
237
. We therefore sought to address if c-KIT also interacts with 
BECN1 and suppresses autophagy in MCPyV+ MCC. Using co-immunostaining of c-KIT 
and BECN1, BECN1 and c-KIT were in very close proximity within the paranuclear dot-like 
  34 
region. To further strengthen the results, the interaction between BECN1 and c-KIT was 
confirmed by co-immunoprecipitation and reciprocal immunoprecipitation assays.  
4.2.3 Silencing of c-KIT induces autophagy and apoptosis in MCPyV+ MCC 
To address the involvement of c-KIT in regulation of autophagy, we silenced c-KIT in WaGa 
cells and evaluated the effect on LC3-II levels with and without bafilomycin A1 treatment 
using Western blotting. The results showed an induction of LC3-II in the absence or presence 
of bafilomycin A1. c-KIT can activate AKT-mTOR signaling, which can also suppress 
autophagy 
238
. We therefore examined whether AKT-mTOR signaling contributes to c-KIT-
mediated autophagy regulation in MCC. Our results showed that silencing of c-KIT led to 
subtle decreases in both phosphorylation statuses of mTOR and/or AKT, suggesting that c-
KIT-mediated autophagy suppression may partly depend on the AKT-mTOR signaling 
pathways.  
         Besides autophagy regulation, we also observed an increase of apoptosis upon silencing 
of c-KIT, as indicated by increased expression of the 89-kDa cleaved PARP. The increased 
expression of cleaved PARP was also noted in the c-KIT-depleted cells with inhibition of 
autophagy, suggesting that the apoptosis was not induced by autophagy. Together, our results 
demonstrate that c-KIT is required for autophagy suppression and cell viability in MCPyV+ 
MCC cells. 
4.2.4 Autophagy can degrade LT protein  
Unexpectedly, we observed reduction of MCPyV LT in the c-KIT-depleted cells and its level 
was restored upon treatment with the bafilomycin A1 autophagy inhibitor. We therefore 
evaluated whether MCPyV LT is degraded by autophagy. Indeed, our results showed that LT 
expression was decreased upon induction of autophagy (by EBSS or Torin-1), and restored 
upon inhibition of autophagy (by bafilomycin A1). To strengthen the results, we are now 
silencing autophagy genes and assess the degradation rate of viral oncoproteins. 
Collectively we uncovered a novel mechanism where the viral truncated LT can promote 
paranuclear retention of c-KIT, and a new role for c-KIT in autophagy regulation through 
interaction with BECN1. 
 
4.3 FUNCTIONAL STUDIES OF MIR-375 AND LDHB IN MCC (PAPER III) 
In Paper I, we identified miR-375 as one of the differentially expressed miRNAs between 
MCPyV+ and MCPyV- MCC tumors. This miRNA is highly abundant in most MCC tumors 
and its high levels in serum samples correlate with tumor burden in MCC 
151
. miR-375 has 
been demonstrated to promote neuroendocrine differentiation in MCPyV- MCC cell lines. 
However, its functional role in MCPyV+ MCC remains undefined. LDHB, one of the known 
targets of miR-375, has been detected in MCC tumors 
239
. In this study, we investigated 
whether miR-375 could regulate LDHB and their functional roles in MCC. 
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4.3.1  miR-375 regulates LDHB levels in MCC 
We first evaluated whether LDHB could be a target of miR-375 in MCC. In consistent with 
higher levels of miR-375 in MCPyV+ than MCPyV- MCC tumors observed in Paper I, miR-
375 levels were also higher in all three MCPyV+ MCC cell lines (WaGa, MKL-1 and MKL-
2) compared to the three MCPyV- MCC cell lines (MCC13, MCC14/2 and MCC26). On the 
other hand, LDHB mRNA and protein levels were higher in the MCPyV- than MCPyV+ 
MCC cell lines. Furthermore, LDHB mRNA levels were also inversely correlated with miR-
375 in MCC tumor samples. Additionally, overexpression of miR-375 in MCPyV- MCC cells 
reduced, and silencing of miR-375 induced, LDHB mRNA and protein levels. These results 
indicate that LDHB is a target of miR-375 in MCC. 
4.3.2  miR-375 overexpression suppresses cell growth and migration in 
MCPyV- MCC cell lines 
To determine the functional role of miR-375 in MCC cells, we overexpressed miR-375 in 
MCPyV– MCC cells using miR-375 expression plasmid or mimic and evaluated the effect on 
functional phenotypes. Our results showed that miR-375 overexpression reduced cell growth, 
as assessed by WST-1 and trypan blue exclusion assays. Furthermore, over-expression of 
miR-375 led to a subtle increase in G1 or G2 phases compared to the negative control. Using 
wound healing scratch assay, we observed a reduction in wound closure rate compared to the 
negative control in miR-375-overexpressing cells. In addition, overexpression of miR-375 
increased the expression of cleaved PARP, an apoptotic marker. Together, our results suggest 
that miR-375 functions as a tumor suppressor in MCPyV- MCC cell lines, by inhibiting cell 
growth and migration, as well as inducing apoptosis. 
4.3.3  Suppression of miR-375 decreases cell growth and increases apoptosis 
in MCPyV+ MCC cell lines 
In MCPyV+ MCC cell lines, inhibition of miR-375, using miRNA sponges, reduced cell 
growth in both WaGa and MKL-1 cell lines, as evaluated by trypan blue exclusion and WST-
1 assays. Concomitantly, suppression of miR-375 led to an increase of apoptosis, as evaluated 
by Annexin V and caspase-3 activity assays. The results indicate that miR-375 is required for 
cell growth and viability in MCPyV+ MCC cells. 
4.3.4  Silencing of LDHB reduces cell growth in MCPyV- MCC cells but 
rescues cell growth suppression mediated by miR-375 inhibition in MCPyV+ 
MCC cells 
We further investigated whether LDHB plays a role in miR-375-mediated cell growth in 
MCPyV+ MCC cell lines. We determined cell growth in cells transfected with miR-375sp 
together with and without siRNAs targeting LDHB, as well as cells transfected with miR-
375sp or vehicles only. Inhibition of miR-375 reduced cell growth and silencing of LDHB 
rescued the cell growth inhibition effect caused by miR-375 suppression. On the other hand, 
silencing of LDHB decreased cell growth and increased apoptosis in MCPyV- MCC cell 
lines.  
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Collectively, our study suggests that LDHB functions as an oncogene in MCPyV- MCC, and 
a tumor suppressor in MCPyV+ MCC cell lines. Given that LDHB is a key enzyme involved 
in energy metabolism, we speculated that the differential role of LDHB could relate to 
different cellular metabolisms in MCPyV+ and MCPyV- cells, which led to the investigations 
in Paper IV. 
 
4.4 MCPYV T-ANTIGENS AND LDHB IN GLYCOLYSIS IN MCC (PAPER IV) 
In Paper III, we have shown that LDHB can regulate cell growth in MCC cells, and 
depending on virus status, LDHB can be an oncogene or a tumor suppressor. Given that 
LDHB is a metabolic enzyme involved in glycolysis and its expression level is associated 
with the virus status, we investigated whether MCPyV T-antigens could regulate LDHB 
levels and its effect on energy metabolism and cell growth. 
4.4.1  MCPyV T-antigens regulate LDHB expression and glycolysis 
Using RT-qPCR and Western blotting, we showed that silencing of MCPyV T-antigens 
increased LDHB expression at mRNA and protein levels in MCPyV+ MCC cells, while 
ectopic expression of MCPyV sT and truncated LT decreased LDHB expression in 
MCPyV- MCC cell lines. Silencing of MCPyV T-antigens also decreased glycolysis rates 
and ectopic expressions of sT and truncated LT increased glycolysis. Cells expressing wild-
type LT did not have consistent effect in MCC13 and MCC14/2 cells; its glycolysis rate 
was similar to the vector control in MCC13 but increased in MCC14/2 cells. Together, our 
results showed that MCPyV sT and truncated LT could suppress LDHB expression and 
promote glycolysis. 
4.4.2  LDHB overexpression reduces cell growth and induces apoptosis in 
MCPyV+ MCC cell lines 
In Paper III, we demonstrated that silencing of LDHB rescued miR-375-mediated cell 
growth suppression in MCPyV+ MCC cell lines. To demonstrate the direct effect of LDHB 
as a suppressor in MCPyV+ cells, we ectopically expressed full-length coding sequence of 
LDHB in WaGa and MKL-1 cell lines. We observed that LDHB overexpression reduced 
cell growth and increased apoptosis in both cell lines, supporting its tumor suppressor role 
in MCPyV+ MCC cells. 
4.4.3  Ectopic expression of LDHB reverses the growth-promoting effect of 
MCPyV oncoproteins 
We next investigated whether the functional role of LDHB is dependent on MCPyV 
oncoproteins by comparing the effects of cells co-transfected with MCPyV T-antigen 
together with and without ectopic LDHB expression in MCPyV- MCC cell lines. Our results 
showed that sT and LT339 increased cell growth in both cell lines, which is consistent with 
the results reported in previous studies 
15,240
. However, the full-length LT did not have 
significant effect on cell growth. Co-transfection of LDHB and sT or LT339 reversed the 
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growth-promoting effect of these viral oncoproteins. Similarly, cells transfected with LDHB 
and sT or LT339 had more apoptotic cells than the cells transfected with sT or LT339. No 
differences were observed for cell growth and apoptosis in cells expressing full-length LT 
with and without ectopic LDHB. These findings suggest that low LDHB level is important 
for cell growth and viability of viral oncoproteins expressing cells, due to reprogramming of 
energy metabolism in the cells. Cells expressing viral oncoproteins may rely on glycolysis for 
promoting cell growth. Increased LDHB expression promotes conversion of lactate to 
pyruvate for the TCA cycle that switches from glycolysis to oxidative phosphorylation. These 
observations led us to investigate whether MCPyV+ and MCPyV- MCC cells are dependent 
on different metabolic activities for cell growth. 
4.4.4 MCPyV + and MCPyV- MCC cells rely on different energy metabolism for 
cell growth 
To address this question, we treated MCC cells with oxamic acid (glycolysis inhibitor) or 
antimycin A (oxidative phosphorylation inhibitor). In MCPyV+ MCC cells, we found that 
oxamic acid-treated cells reduced glycolysis in both cell lines, while treatment with antimycin 
A increased glycolysis due to increased lactate production 
226
. Inhibition of glycolysis 
reduced cell growth in MCPyV+ MCC cell lines, while inhibition of oxidative 
phosphorylation had no effect on cell growth. In MCPyV- MCC cell lines, antimycin A 
treatment reduced oxygen consumption rate (OCR), while oxamic acid treatment did not have 
any effect on OCR. Antimycin A treatment inhibited cell growth in MCPyV- cell lines, but 
not with oxamic acid.  
 
In summary, our findings revealed that MCPyV oncoproteins suppress LDHB expression and 
induce glycolysis for promoting cell growth and viability in MCC. MCPyV+ and MCPyV- 
MCC cells are dependent on different energy metabolism for cell growth, which leads us to 
propose targeting metabolism as an alternative strategy for treating MCC patients. 
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5 CONCLUSIONS 
 
MCPyV oncoproteins (sT and truncated LT) clearly play important roles in MCC 
tumorigenesis. This thesis explored the involvement of the viral oncoproteins in regulating 
miRNA expressions, autophagy and metabolism. The main findings of this thesis are 
summarized below: 
 
 MCPyV T-antigens regulate a subset of miRNAs, including miR-375, miR-30a-3p and 
miR-30a-5p, through the DnaJ domain of viral T-antigen (Paper I). 
 
 MCPyV oncoproteins can suppress autophagy via multiple mechanisms, including 
miRNA regulation of multiple autophagy genes and c-KIT interaction with BECN1  (Papers 
I and II). 
 
 miR-375 can regulate autophagy by targeting ATG7 and SQSTM1, and metabolism by 
suppressing LDHB (Papers I and III). 
 
 c-KIT can regulate autophagy and apoptosis in MCPyV+ MCC cells (Paper II). 
 
 The Vam6p of MCPyV truncated LT is required for paranuclear retention of c-KIT 
(Paper II). 
 
 miR-375 and LDHB have different functions in MCC cells with and without MCPyV 
(Paper III). 
 
 Low level of LDHB is required for cell growth and viability in MCPyV+ cells (Paper 
IV). 
 
 MCPyV+ MCC cell lines are dependent on glycolysis and MCPyV- MCC cell lines 
rely on oxidative phosphorylation for cell growth and viability (Paper IV). 
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6 FUTURE PERSPECTIVE 
 
This thesis work describes new functions of MCPyV T-antigens, i.e. autophagy suppression 
and reprogramming energy metabolism. Mechanistically, the viral oncoproteins could 
suppress autophagy through miRNA regulations and c-KIT interaction with BECN1. 
Suppression of autophagy is crucial to sustain MCPyV T-antigen expression and cell viability 
in MCC (Papers I and II). On the other hand, MCPyV T-antigens can reprogram energy 
metabolism through regulation of LDHB expression levels (Paper IV) or other glycolytic 
genes, such as MCT1 
75
. These findings reveal the involvement of autophagy and metabolism 
reprogramming in MCC tumorigenesis. Further studies investigating the functional impact of 
autophagy suppression and glycolysis may facilitate our understanding the role of the viral 
oncoproteins in MCC development. 
In Paper I, we demonstrated that MCPyV T-antigens could regulate specific miRNAs at 
post-transcriptional level. Although we identified that the DnaJ domain of the viral T-
antigens is crucial for miRNA regulation, the molecular mechanism of this regulation is still 
unclear. Within the DnaJ domain, there is an Hsc70 binding site. Hsc70 can bind to the AU-
rich elements (AREs) of Bim mRNA and regulate its mRNA stability 
241
. This leads us to 
hypothesize that the interaction between MCPyV T-antigens and Hsc70 can increase mRNA 
stability and/or translation of miRNA processing gene(s).  
In Paper II, we have shown that c-KIT is mainly localized on Golgi apparatus; however it is 
still unclear whether c-KIT accumulated on the Golgi after the early secretory pathway or 
endocytosis from the plasma membrane. Although we showed that c-KIT interacts with 
BECN1, the interaction sites between c-KIT and BECN1 and the mechanism of this 
interaction that contributes to autophagy suppression remain to be determined.  
In Papers III and IV, we demonstrated that MCPyV oncoproteins could regulate LDHB 
expressions and glycolysis; it is still unclear how these viral oncoproteins regulate LDHB 
expression, which leads to change of the energy metabolisms in MCCs.  
Although recent studies revealed a positive outcome with anti-PD-1 or anti-PD-L1 treatment 
in advanced MCC patients, the long-term outcomes of these patients remain unknown; 
moreover, half of them are still refractory to these immune-checkpoint inhibitors. 
Identification of alternative treatment options for advanced MCC patients are still warranted. 
Delineating the functional roles of MCPyV oncoproteins in MCC may lead to identification 
of new avenues for developing novel therapeutic approaches for MCC treatment.  
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